Dermatology focuses on the health of the skin, hair, and nails. Learn about the diagnosis and treatment of acne, eczema, skin cancer, and cosmetic procedures.
Send us all your questions or requests, and our expert team will assist you.
The overview and definition of basal cell carcinoma (BCC) provides essential insight for patients and caregivers seeking clear, reliable information about this common skin cancer. BCC accounts for approximately 80% of all skin cancers worldwide, making it a critical topic for anyone planning a full‑body health assessment or considering dermatologic care abroad. This page is designed for international patients who may travel to Liv Hospital for expert evaluation, diagnosis, and treatment. We will explore the nature of BCC, its causes, how it presents clinically, the latest staging methods, treatment options—including advanced robotic and minimally invasive techniques—and the best practices for follow‑up care and prevention.
Understanding the disease from an overview and definition perspective empowers patients to make informed decisions, coordinate care across borders, and engage confidently with their healthcare team. Throughout the following sections, you will find detailed explanations, practical lists, and comparative tables that reflect Liv Hospital’s commitment to transparent, patient‑centered communication.
Basal cell carcinoma is a malignant tumor that originates from the basal cells of the epidermis, the deepest layer of the skin’s outermost surface. Although it grows slowly and rarely spreads to distant organs, BCC can cause significant local tissue damage if left untreated. The disease typically appears on sun‑exposed areas such as the face, neck, and hands, reflecting a strong link to ultraviolet (UV) radiation.
Key characteristics of BCC include:
From an overview and definition standpoint, BCC is distinguished from other skin cancers by its histological appearance—clusters of basaloid cells with peripheral palisading—and by its generally favorable prognosis when managed early. Epidemiological data show that individuals with lighter skin tones and a history of chronic sun exposure are most at risk, underscoring the importance of preventive skin care.
While the exact genetic triggers of basal cell carcinoma remain under investigation, several well‑established risk factors contribute to its development. Understanding these factors helps patients assess personal risk and adopt protective measures.
Major contributors include:
Table 1 compares the relative impact of UV exposure patterns on BCC risk:
By recognizing these risk elements, patients can collaborate with Liv Hospital’s dermatology team to create personalized surveillance and prevention plans.
Basal cell carcinoma often manifests as a painless, pearly or translucent nodule with visible telangiectasia (tiny blood vessels). Other presentations may include a flat, scaly lesion (superficial BCC) or a scar‑like, indurated plaque (morpheaform BCC). Because early lesions can mimic benign skin conditions, accurate diagnosis relies on a combination of visual assessment and histopathological confirmation.
Diagnostic steps typically include:
At Liv Hospital, the dermatology department utilizes state‑of‑the‑art dermatoscopes and digital pathology to ensure rapid, accurate diagnosis. An overview and definition of the diagnostic pathway emphasizes the importance of early detection: the sooner a BCC is identified, the more likely it can be treated with minimally invasive techniques, preserving both function and aesthetics.
Although basal cell carcinoma rarely metastasizes, precise staging is essential for guiding treatment intensity and predicting outcomes. The American Joint Committee on Cancer (AJCC) 8th edition classifies BCC using a TNM system focused on tumor size, depth of invasion, and presence of high‑risk features.
Table 2 outlines the primary staging categories:
Prognosis is excellent for early‑stage disease, with 5‑year survival rates exceeding 95%. However, advanced stages require multidisciplinary care, often involving dermatology, surgical oncology, radiation oncology, and medical oncology—a collaborative model readily available at Liv Hospital.
The therapeutic landscape for basal cell carcinoma ranges from simple surgical excision to cutting‑edge targeted therapies. Treatment selection depends on tumor size, location, histologic subtype, and patient preferences.
Current modalities include:
Liv Hospital integrates advanced technologies such as robotic‑assisted surgery and high‑resolution intra‑operative imaging to enhance precision, especially in anatomically complex regions like the peri‑ocular area. An overview and definition of treatment pathways underscores the hospital’s capacity to tailor therapy—whether a patient seeks a quick outpatient procedure or requires a comprehensive multimodal approach.
After successful treatment, diligent follow‑up is crucial to detect recurrence early and to reinforce preventive behaviors. Recommended surveillance includes:
Preventive measures also involve lifestyle modifications, such as quitting smoking and maintaining a healthy immune system, which can reduce the likelihood of new skin cancers. Liv Hospital’s international patient services team assists travelers with post‑treatment follow‑up plans, coordinating virtual consultations and providing multilingual educational resources.
Liv Hospital combines JCI accreditation, cutting‑edge technology, and a dedicated international patient department to deliver world‑class dermatologic care. Our multidisciplinary teams specialize in skin oncology, offering personalized treatment plans that align with each patient’s cultural and logistical needs. From seamless appointment scheduling to interpreter services and comfortable accommodation, we ensure a stress‑free experience for patients traveling from abroad.
Ready to take the next step toward expert basal cell carcinoma care? Contact Liv Hospital today to schedule a virtual consultation, and let our specialists guide you through a safe, effective treatment journey.
Liv Hospital Ulus
Asst. Prof. MD. Ayşe Deniz Akkaya
Dermatology
Liv Hospital Ulus
Asst. Prof. MD. Nazlı Caf
Dermatology
Liv Hospital Ulus
Prof. MD. İlteriş Oğuz
Dermatology
Liv Hospital Ulus
Spec. MD. Ömer Gezdur
Dermatology
Liv Hospital Vadistanbul
Assoc. Prof. MD. Ece Altun
Dermatology
Liv Hospital Vadistanbul
Prof. MD. Sevilay Oğuz Kılıç
Dermatology
Liv Hospital Vadistanbul
Spec. MD. Marziyeh Javadpour
Dermatology
Liv Hospital Vadistanbul
Spec. MD. Meryem Ayşit
Dermatology
Liv Hospital Bahçeşehir
Assoc. Prof. MD. Nadir Göksügür
Dermatology
Liv Hospital Bahçeşehir
Spec. MD. Esengül Kaya
Dermatology
Liv Hospital Bahçeşehir
Spec. MD. Vedat Ertunç
Dermatology
Liv Hospital Bahçeşehir
Spec. MD. Özlem İpek
Dermatology
Liv Hospital Topkapı
Spec. MD. Betül Kızılkan
Dermatology
Liv Hospital Topkapı
Spec. MD. Gizem Gökçedağ Ünsal
Dermatology
Liv Hospital Ankara
Asst. Prof. MD. Caner Demircan
Dermatology
Liv Hospital Ankara
Spec. MD. Aylin Gözübüyükoğulları
Dermatology
Liv Hospital Ankara
Spec. MD. Elçin Akdaş
Dermatology
Liv Hospital Ankara
Spec. MD. Vahid Ahmadi
Dermatology
Liv Hospital Gaziantep
Spec. MD. Hatice Kübra Çakı
Dermatology
Liv Hospital Samsun
Asst. Prof. MD. Gül Şekerlisoy Tatar
Dermatology
Liv Hospital Samsun
Spec. MD. Ayşe İdil Baş
Dermatology
Liv Bona Dea Hospital Bakü
Spec. MD. İRFAN QEHREMANOV
Dermatology
Asst. Prof. MD. A. Deniz Akkaya
Dermatology
MD. Gül Şekerlisoy Tatar
Dermatology
Send us all your questions or requests, and our expert team will assist you.
Basal cell carcinoma originates in the deepest layer of the epidermis and grows slowly, rarely metastasizing but capable of causing significant local tissue damage. It is the most frequent skin cancer, representing roughly four‑fifths of all cases globally. Because it typically appears on sun‑exposed areas, early detection is crucial. When treated early, the prognosis is excellent, with five‑year survival rates above 95%.
The primary environmental cause of BCC is chronic or intermittent ultraviolet (UV) radiation from sunlight or tanning beds. Individuals with light skin, hair, and eye color have less melanin protection and are at higher risk. Incidence rises sharply after age 50. Immunosuppressed patients, such as organ‑transplant recipients, and those with genetic conditions like Gorlin‑Goldberg syndrome also face increased susceptibility. Lifestyle factors such as smoking can further elevate risk.
Clinicians first assess the lesion visually, often using a dermatoscope to identify characteristic vascular patterns and pearly nodules. A skin biopsy—excisional, incisional, or punch—is then performed to obtain tissue for microscopic analysis. Histopathology confirms BCC by revealing basaloid cell nests with peripheral palisading. For lesions suspected of deep invasion, high‑frequency ultrasound or MRI may be employed to evaluate extent before treatment planning.
Treatment choice depends on tumor size, location, histologic subtype, and patient preference. Standard surgical excision removes the lesion with a 4‑5 mm margin, while Mohs micrographic surgery offers tissue‑sparing precision and the highest cure rates for cosmetically sensitive areas. Superficial BCC may be treated with topical imiquimod or 5‑fluorouracil. Cryotherapy is suitable for small, well‑defined lesions. Advanced or metastatic cases can be managed with hedgehog pathway inhibitors such as vismodegib or sonidegib, and clinical trials are exploring checkpoint inhibitor immunotherapies.
The AJCC 8th edition classifies BCC by tumor size, depth, and high‑risk features (e.g., perineural invasion). Stage I (≤2 cm, low‑risk) is usually treated with simple excision or Mohs surgery and has >95% five‑year survival. Stage II involves larger or high‑risk tumors and may need Mohs plus adjuvant radiotherapy. Stage III denotes locally advanced disease with bone or cartilage invasion, requiring combined surgery, radiation, and possibly systemic therapy. Stage IV, the rare metastatic stage, is managed with targeted or immunotherapy. Prognosis declines with higher stage, emphasizing the importance of early detection.
After treatment, regular clinical skin checks are advised every three to six months during the first two years to catch recurrences early, followed by annual visits. Patients are educated on monthly full‑body self‑examinations and may use digital dermoscopy imaging to monitor scar tissue and new lesions. Sun‑protection measures—broad‑spectrum SPF 50+ sunscreen, protective clothing, and avoidance of peak UV hours—are reinforced. Lifestyle changes such as smoking cessation and maintaining immune health further reduce future risk.
Liv Hospital combines world‑class dermatology expertise with cutting‑edge tools like robotic‑assisted surgery and high‑resolution intra‑operative imaging, ensuring precise treatment even in complex anatomical regions. Its JCI accreditation guarantees high safety and quality standards. The hospital’s International Patient Department handles visa assistance, interpreter services, accommodation, and virtual follow‑up, making the entire journey seamless for patients traveling from abroad.
BlogDermatologyApr 10, 2026Did you know over 10 million people in the U.S. have allergies bad enough for allergy immunotherapy? This t...
BlogDermatologyApr 10, 2026Nearly 1 in 5 people who get a chemical peel face skin irritation or reaction. This makes taking good care ...
BlogDermatologyApr 10, 2026More than 100 million people in the United States deal with allergies every year. Finding good allergy reli...
BlogDermatologyApr 10, 2026A dermatopathologist is a doctor who specializes in skin diseases. They look at tissue samples under a micr...
BlogDermatologyApr 09, 2026We focus on aesthetic dermatology, which aims to improve beauty and health. An aesthetic dermatologist is k...
BlogDermatologyApr 09, 2026Discover the vital role of melanocytes in skin health and protection. Learn about their anatomy, function, ...
Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.
Start Chat on WhatsApp or call us at +90 530 174 26 75